At the height of the COVID-19 pandemic in 2021, VITT emerged as a new disease following adenovirus vector-based vaccines—notably the Oxford-AstraZeneca vaccine. VITT was found to be caused by an ...

An inhalable version of a single-shot, adenovirus-based viral vector vaccine might provide a new option for COVID-19 vaccination. In October 2021, the World Health Organization set a target for ...

One avenue for new vaccine development is mucosal vaccines. In theory, dosing the vaccine directly into the respiratory tract ...

An upside of using vectored vaccines is that they are easy and relatively cheap to make. The adenovirus vector, for example, can be grown up in cells and used for various vaccines. Once you make a ...

In 2012, researchers at the University of Oxford created ChAdOx1, a virus vector vaccine based on a modified simian adenovirus. The researchers chose a simian adenovirus because “if you use a ...

How it works Convidencia is a viral vector vaccine using adenovirus five. With a viral vector, there is essentially a viral particle, which is programmed not to replicate. So, what is administered ...

McMaster University has developed an inhaled COVID-19 vaccine and studies are starting phase-two of human trials.

Thrombosis with Thrombocytopenia Syndrome (TTS) is a rare yet serious condition linked to certain COVID-19 vaccines, notably adenovirus vector vaccines like AstraZeneca and Johnson & Johnson's ...

Viral vectors used in vaccines do not affect or interact with your DNA. The tough protein coat of the adenovirus helps protect the DNA genetic instructions inside. As a result, viral vector vaccines ...

The Imbokodo study (also known as HVTN 705) used a ‘prime’ vaccine consisting of an adenovirus vector that delivered a ‘mosaic’ of HIV envelope and internal proteins from four HIV subtypes designed to ...

Hyderabad: Bharat Biotech International Limited (BBIL), a pioneer in affordable indigenous vaccine development and ...